This study is a single-center observational investigation aimed at systematically exploring the key molecular features influencing the prognosis of malignant tumors by integrating multidimensional clinical information with multi-omics molecular data. The goal is to provide a critical scientific basis for constructing precise prognostic prediction models, identifying potential therapeutic targets, and optimizing clinical treatment strategies. The study plans to consecutively enroll adult patients with histologically confirmed malignant tumors who received antitumor therapy at our hospital between January 2017 and December 2025. Clinical data (including demographic characteristics, tumor pathology information, treatment histories, and survival follow-up data) will be systematically collected from electronic medical records. Additionally, tumor tissue or blood samples will be obtained from the patients for sequencing, staining, ELISA, drug sensitivity testing, and flow cytometry analysis to comprehensively characterize the genomic features, immune microenvironment, and cellular heterogeneity of the tumors.
Study Type
OBSERVATIONAL
Enrollment
500
Patients receiving immunotherapies such as immune checkpoint inhibitors. Immunotherapy can be administered as first-line or subsequent treatment, or as part of combination therapy, integrated with modalities such as surgery, chemotherapy, radiotherapy, and targeted therapy.
Patients for whom radiotherapy is the primary or a significant component of their treatment. Radiotherapy may be administered with curative, adjuvant, or palliative intent, and can be given alone or in combination with surgery, chemotherapy, targeted therapy, immunotherapy, etc.
Patients undergoing curative tumor resection as their primary treatment modality. Surgery may be performed with or without neoadjuvant/adjuvant chemotherapy, radiotherapy, targeted therapy, or immunotherapy.
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China
RECRUITINGOverall Survival (OS)
The time from the start of treatment to death from any cause. Patients who are alive at the last follow-up are censored.
Time frame: From date of treatment initiation until date of death or last follow-up, assessed up to 5 years.
Progression-Free Survival (PFS)
The time from the start of treatment to the first documented disease progression (per RECIST criteria) or death from any cause, whichever occurs first.
Time frame: From date of treatment initiation until date of progression or death, assessed up to 5 years.
Pathological Complete Response (pCR)
The absence of residual invasive cancer in the resected tumor specimen and lymph nodes after neoadjuvant therapy, as determined by histopathological evaluation.
Time frame: At the time of surgery following neoadjuvant treatment, typically within 4-6 weeks after completion of therapy.
Major Pathologic Response (MRP)
The presence of ≤10% residual viable tumor cells in the resected tumor specimen after neoadjuvant therapy, assessed by pathological examination.
Time frame: At the time of surgery following neoadjuvant treatment, typically within 4-6 weeks after completion of therapy.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.